Welcome to our dedicated page for Royalty Pharma plc news (Ticker: RPRX), a resource for investors and traders seeking the latest updates and insights on Royalty Pharma plc stock.
Royalty Pharma plc (Nasdaq: RPRX) is the leading acquirer of revenue-producing intellectual property, primarily focusing on royalty interests in marketed and late-stage biopharmaceutical products. Established in 1996, the company has built a robust portfolio with over $13 billion in assets and has invested nearly $5.8 billion to date. Royalty Pharma excels in acquiring and managing diverse royalty interests across various therapeutic areas, mitigating the common risks associated with biopharmaceutical investments.
Royalty Pharma's portfolio includes royalties on more than 35 commercial products, such as AbbVie and Johnson & Johnson's Imbruvica for blood cancers, Biogen's Tysabri for multiple sclerosis, and Vertex's cystic fibrosis drugs. The company also holds interests in 14 development-stage products, demonstrating its commitment to funding innovation in the biopharmaceutical sector.
Recent achievements include a $525 million acquisition of royalties and milestones on frexalimab, a promising therapy developed by Sanofi for multiple sclerosis and other immune-mediated diseases. This transaction enhances Royalty Pharma's development-stage portfolio, reinforcing its potential for long-term growth.
Financially, Royalty Pharma reported first-quarter 2024 results reflecting strong royalty receipts growth, driven by key therapies like Trelegy and Vertex’s cystic fibrosis franchise. The company maintains a solid liquidity position with $843 million in cash and cash equivalents and a total debt of $6.3 billion.
Royalty Pharma's strategic partnerships span a broad spectrum of innovators, from academic institutions and research hospitals to leading global pharmaceutical companies. This extensive collaboration network underscores the company's pivotal role in advancing medical research and providing essential funding for late-stage clinical trials and new product launches.
For more information, visit www.royaltypharma.com.
Royalty Pharma (Nasdaq: RPRX) announced a collaboration with MSCI Inc. to create new thematic indexes focused on innovation in the life sciences, specifically targeting virology and oncology. This partnership will leverage Royalty Pharma's expertise in medical conditions and clinical trials to assist MSCI in developing index methodologies. The new indexes aim to capture performance metrics of companies delivering advanced therapeutic treatments. The launch is expected later this year, showcasing Royalty Pharma's commitment to monetizing its intellectual capital in life sciences.
The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved a dividend payment of $0.17 per class A share for the second quarter of 2021. This dividend will be paid on June 15, 2021, to shareholders on record as of May 20, 2021. Royalty Pharma is recognized as the largest purchaser of biopharmaceutical royalties and plays a significant role in funding innovation in the biopharmaceutical sector, partnering with a range of companies to enhance their product launches and clinical trials.
Royalty Pharma has acquired Dicerna's royalty interest in OXLUMO for $180 million upfront and up to $60 million in sales-based milestones. OXLUMO, approved for treating primary hyperoxaluria type 1, is marketed by Alnylam Pharmaceuticals. This deal will extend Dicerna's cash runway into 2024, enhancing its ability to fund clinical operations, including the development of its lead candidate, nedosiran. Both companies highlight the innovative nature of RNAi therapeutics as a significant focus of this transaction.
Dicerna Pharmaceuticals (Nasdaq: DRNA) has agreed to sell its royalty interest in OXLUMO™ to Royalty Pharma (Nasdaq: RPRX) for an upfront payment of $180 million, plus potential sales-based milestones of up to $60 million. OXLUMO is FDA and EMA approved for treating primary hyperoxaluria type 1 and marketed by Alnylam Pharmaceuticals. This transaction is expected to extend Dicerna's cash runway into 2024, supporting ongoing clinical plans. The deal reflects Dicerna's commitment to addressing unmet medical needs in rare diseases, specifically primary hyperoxaluria.
Royalty Pharma (RPRX) has acquired royalty interests in Cabometyx and Cometriq from GlaxoSmithKline (GSK) for an upfront payment of $342 million, plus up to $50 million contingent on future regulatory approvals for prostate and lung cancer. Cabometyx is already approved for advanced renal cell carcinoma and hepatocellular carcinoma. In 2020, sales of Cabometyx were $742 million, and Cometriq's sales were €289 million. GSK retains a 3% royalty on worldwide net sales of cabozantinib products, while Royalty Pharma will receive royalties in non-U.S. markets and U.S. royalties through September 2026.
The Board of Directors of Royalty Pharma (Nasdaq: RPRX) has appointed Henry A. Fernandez as Lead Independent Director. Fernandez, CEO of MSCI, will also serve on the Audit Committee. CEO Pablo Legorreta highlighted Fernandez's leadership and business acumen, noting the expected benefits for Royalty Pharma's governance and operations. Fernandez expressed his commitment to maintaining strong oversight in his new role. Royalty Pharma, established in 1996, is the largest buyer of biopharmaceutical royalties and funds innovation in the industry.
Royalty Pharma (RPRX) reported strong financial results for Q4 2020, with net cash from operating activities rising 18% to $566 million. Adjusted Cash Receipts grew 9% to $484 million, driven by key assets like the cystic fibrosis franchise and Imbruvica. The company executed $2.4 billion in acquisitions, enhancing its diverse portfolio. For 2021, RPRX expects Adjusted Cash Receipts between $1,910 million and $1,960 million, reflecting a robust outlook with a projected CAGR of 7%-10% from 2020-2025. The firm also maintains a leading market share in biopharma royalty funding.
Royalty Pharma plc (Nasdaq: RPRX) will announce its fourth quarter 2020 financial results on February 17, 2021, prior to U.S. market opening. A conference call will follow at 8:00 a.m. Eastern Time, accessible via phone or a live webcast on the company's Investors page. Royalty Pharma is recognized as the largest buyer of biopharmaceutical royalties, maintaining a diverse portfolio that includes royalties from over 45 leading therapies, such as Imbruvica and Xtandi. The company focuses on funding innovation in the biopharmaceutical sector, facilitating late-stage clinical trials and new product launches.
Royalty Pharma (RPRX) has announced its acquisition of Minerva Neurosciences' royalty interest in seltorexant, an antidepressant, for an upfront payment of $60 million and up to $95 million in milestone payments. Seltorexant, currently in Phase 3 for treating major depressive disorder with insomnia, is developed by Janssen Pharmaceutica. The deal is expected to enhance Royalty Pharma's portfolio, while Minerva aims to use proceeds for the development of its lead compound, roluperidone, targeting negative schizophrenia symptoms.
Royalty Pharma (RPRX) has declared a $0.17 dividend per class A share for Q1 2021, marking a 13% increase over the previous quarter. This reflects the company's commitment to returning value to shareholders. The dividend will be paid on March 15, 2021, to shareholders on record as of February 19, 2021. As the largest buyer of biopharmaceutical royalties, Royalty Pharma continues to fund innovation in the sector, collaborating with various biotech and pharmaceutical companies.
FAQ
What is the current stock price of Royalty Pharma plc (RPRX)?
What is the market cap of Royalty Pharma plc (RPRX)?
What does Royalty Pharma do?
What are some key products in Royalty Pharma’s portfolio?
How does Royalty Pharma fund innovation?
What is the company's financial position?
What recent acquisitions has Royalty Pharma made?
How does Royalty Pharma mitigate risks?
Who are Royalty Pharma’s partners?
What are Royalty Pharma’s recent financial results?
What is Royalty Pharma’s strategy?
Where can I find more information about Royalty Pharma?
